Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD...

Core Insights - Longeveron Inc. presented findings on laromestrocel, a stem cell therapy for mild Alzheimer's disease, at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting its potential to reduce neuroinflammation and improve cognitive function [1][2][8] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines for rare pediatric and chronic aging-related conditions, with laromestrocel as its lead investigational product [10] - The company has received multiple FDA designations for laromestrocel, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its Alzheimer's disease program [2][10] Clinical Trial Findings - The CLEAR MIND study demonstrated that laromestrocel treatment led to a significant reduction in free water fraction, indicating decreased neuroinflammation in key brain regions associated with Alzheimer's disease, particularly the hippocampus and temporal lobe [5][6][7] - Results showed that 13 out of 14 brain regions exhibited improvement in neuroinflammation, with a notable dose-response effect observed in the hippocampus [5][6] - The treatment was associated with clinical benefits, including improved cognitive function and reduced brain atrophy, reinforcing the therapeutic potential of laromestrocel [2][5][8] Mechanism of Action - Laromestrocel is derived from mesenchymal stem cells (MSCs) and targets neuroinflammation and microvascular dysfunction, with the potential to stimulate tissue regeneration [4][9] - The therapy's anti-inflammatory effects were supported by MRI assessments, correlating with preservation of hippocampal volume and positive clinical outcomes [7][8]